By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aqualis ASA (Formerly Known as Clavis Pharma ASA) 

Sjølyst Plass 2

Oslo    NO-0278   Norway
Phone: 47-23-01-49-90 Fax: 47-24-11-09-51


Company News
Clavis Pharma ASA Stops Elacytarabine Development on Negative Ph3 Trial in AML 4/2/2013 7:56:18 AM
Skyline Diagnostics B.V. and Clavis Pharma ASA to Collaborate on Patient Selection Biomarker Discovery for Leukemia Drug Elacytarabine 9/6/2011 12:07:52 PM
Norway's Clavis Pharma ASA Raises 19 Million Euros 11/18/2010 7:59:29 AM
Clavis Pharma ASA and Clovis Oncology Sign New $205 Million Deal For Pancreatic Cancer Drug in Asia And Rest of World 11/11/2010 7:59:20 AM
German Cancer Research Center Finds Fatty Acid to Enhance Anticancer Drug 5/7/2010 10:17:06 AM
Clavis Pharma ASA Appoints Olav Hellebo as Chief Executive Officer 1/8/2010 8:38:40 AM
Clavis Pharma ASA: Positive Phase II Clinical Data For Clavis Pharma's Elacytarabine Presented At American Society of Hematology Annual Meeting 12/7/2009 11:28:13 AM
Norway's Clavis Pharma ASA Signs $380 Million Cancer Drug Deal with Clovis Oncology (JOBS) 11/24/2009 6:48:11 AM
Clavis Pharma ASA Raises $20 Million in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates 6/26/2009 7:14:38 AM
Clavis Pharma ASA Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6/17/2009 7:19:02 AM